Heart and Vessels

, Volume 31, Issue 5, pp 758–770 | Cite as

Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction

  • Akira Funada
  • Hideaki Kanzaki
  • Teruo Noguchi
  • Yoshiaki Morita
  • Yasuo Sugano
  • Takahiro Ohara
  • Takuya Hasegawa
  • Hiromi Hashimura
  • Hatsue Ishibashi-Ueda
  • Masafumi Kitakaze
  • Satoshi Yasuda
  • Hisao Ogawa
  • Toshihisa Anzai
Original Article

Abstract

Hypertrophic cardiomyopathy (HCM) with systolic dysfunction carries a poor prognosis. Although late gadolinium enhancement (LGE) on cardiac magnetic resonance is associated with adverse cardiac events in HCM and is inversely related to left ventricular ejection fraction (LVEF), it is unknown whether LGE or LVEF more accurately predicts adverse cardiac events in HCM with systolic dysfunction. We retrospectively assessed the extent of LGE with a threshold of 6 standard deviations in 46 consecutive HCM patients with systolic dysfunction defined as LVEF <50 % (average 35 ± 12 %) who underwent cardiac magnetic resonance (35 males, mean age 59 ± 14 years). They were followed up over 1755 ± 594 days. The composite adverse cardiac events end point included cardiovascular death, lethal arrhythmia, cardioembolic stroke, and unplanned heart failure hospitalization. LGE was detected in all patients, and the mean extent was 30 ± 15 %. Twenty-nine patients developed adverse cardiac events. Multivariate Cox proportional hazard analysis revealed the extent of LGE as a good independent predictor of adverse cardiac events. Risk increased with the extent of LGE (hazard ratio = 1.62/10 % increase in LGE, 95 % confidence interval = 1.23–2.15, p < 0.001). LVEF was inversely related to the extent of LGE (r = −0.44; p = 0.002) and was also an independent predictor of adverse cardiac events. Risk decreased with LVEF (hazard ratio = 0.68/10 % increase in LVEF, 95 % confidence interval = 0.51–0.91, p = 0.010). The Akaike information criterion evaluating the fit of a model demonstrated that the extent of LGE was a better independent predictor of MACE than LVEF (Akaike information criterion = 172.20 and 178.09, respectively).The extent of LGE was a good independent predictor of adverse cardiac events and reflected mortality and morbidity more precisely than LVEF in HCM with systolic dysfunction.

Keywords

Hypertrophic cardiomyopathy Cardiac magnetic resonance Late gadolinium enhancement Prognosis 

References

  1. 1.
    Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308–1320PubMedGoogle Scholar
  2. 2.
    Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212–2218CrossRefPubMedGoogle Scholar
  3. 3.
    Cannan CR, Reeder GS, Bailey KR, Melton LJ 3rd, Gersh BJ (1995) Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 92:2488–2495CrossRefPubMedGoogle Scholar
  4. 4.
    Kawashiri MA, Hayashi K, Konno T, Fujino N, Ino H, Yamagishi M (2014) Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels 29:129–141CrossRefPubMedGoogle Scholar
  5. 5.
    Fujita E, Nakanishi T, Nishizawa T, Hagiwara N, Matsuoka R (2013) Mutations in the cardiac troponin T gene show various prognoses in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels 28:785–794CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY (2009) Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 54:242–249CrossRefPubMedGoogle Scholar
  7. 7.
    Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J, Seidman CE (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363:552–563CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, Task Force on Clinical Expert Consensus Documents, American College of Cardiology, Committee for Practice Guidelines. European Society of Cardiology (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713CrossRefPubMedGoogle Scholar
  9. 9.
    McKenna WJ, Behr ER (2002) Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 87:169–176CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874CrossRefPubMedGoogle Scholar
  11. 11.
    Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:875–887CrossRefPubMedGoogle Scholar
  12. 12.
    Kwong RY, Farzaneh-Far A (2011) Measuring myocardial scar by CMR. JACC Cardiovasc Imaging 4:157–160CrossRefPubMedGoogle Scholar
  13. 13.
    Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260–2264CrossRefPubMedGoogle Scholar
  14. 14.
    Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3:51–58CrossRefPubMedGoogle Scholar
  15. 15.
    Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ (2008) Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1:184–191CrossRefPubMedGoogle Scholar
  16. 16.
    Green JJ, Berger JS, Kramer CM, Salerno M (2012) Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy JACC Cardiovasc. Imaging 5:370–377Google Scholar
  17. 17.
    Alla VM, Koneru S, Hunter C, Mooss A (2012) LGE and the risk of sudden death in HCM. JACC Cardiovasc Imaging 5:761–762CrossRefPubMedGoogle Scholar
  18. 18.
    Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495CrossRefPubMedGoogle Scholar
  19. 19.
    Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2013) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels 28:742–749CrossRefPubMedGoogle Scholar
  20. 20.
    Hen Y, Iguchi N, Utanohara Y, Takada K, Machida H, Takayama M, Sumiyoshi T (2014) Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 78:929–937CrossRefPubMedGoogle Scholar
  21. 21.
    Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-Edwards A, Wintersperger BJ, Crean A (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6:587–596CrossRefPubMedGoogle Scholar
  22. 22.
    Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114:216–225CrossRefPubMedGoogle Scholar
  23. 23.
    Fernández A, Vigliano CA, Casabé JH, Diez M, Favaloro LE, Guevara E, Favaloro RR, Laguens RP (2011) Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol 108:548–555CrossRefPubMedGoogle Scholar
  24. 24.
    Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L, Lofiego C, Boriani G, Prandstraller D, Picchio FM, Branzi A, Rapezzi C (2005) Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 46:1543–1550CrossRefPubMedGoogle Scholar
  25. 25.
    Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5:535–546CrossRefPubMedGoogle Scholar
  26. 26.
    Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O’Donnell C, Lesser JR, Manning WJ, Maron MS (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106:261–267CrossRefPubMedGoogle Scholar
  27. 27.
    Yacoub MH, Olivotto I, Cecchi F (2007) ‘End-stage’ hypertrophic cardiomyopathy: from mystery to model. Nat Clin Pract Cardiovasc Med 4:232–233CrossRefPubMedGoogle Scholar
  28. 28.
    Hamada T, Kubo T, Kitaoka H, Hirota T, Hoshikawa E, Hayato K, Shimizu Y, Okawa M, Yamasaki N, Matsumura Y, Yabe T, Takata J, Doi YL (2010) Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy. Clin Cardiol 33:E24–E28CrossRefPubMedGoogle Scholar
  29. 29.
    Argulian E, Messerli FH, Aziz EF, Winson G, Agarwal V, Kaddaha F, Kim B, Sherrid MV (2013) Antihypertensive therapy in hypertrophic cardiomyopathy. Am J Cardiol 111:1040–1045CrossRefPubMedGoogle Scholar
  30. 30.
    Kono AK, Yamada N, Higashi M, Kanzaki S, Hashimura H, Morita Y, Sakuma T, Noguchi T, Naito H, Sugimura K (2011) Dynamic late gadolinium enhancement simply quantified using myocardium to lumen signal ratio: normal range of ratio and diffuse abnormal enhancement of cardiac amyloidosis. J Magn Reson Imaging 34:50–55CrossRefPubMedGoogle Scholar
  31. 31.
    Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, Amaki M, Kanzaki H, Okamura H, Kamakura S, Shimizu W, Anzai T, Kitakaze M (2014) Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100:1165–1172CrossRefPubMedGoogle Scholar
  32. 32.
    Harrigan CJ, Peters DC, Gibson CM, Maron BJ, Manning WJ, Maron MS, Appelbaum E (2011) Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 258:128–133CrossRefPubMedGoogle Scholar
  33. 33.
    Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Petryka J, Dabrowski M, Kepka C, Ruzyllo W (2010) Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol 74:e149–e153CrossRefPubMedGoogle Scholar
  34. 34.
    Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ (2006) Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48:1977–1985CrossRefPubMedGoogle Scholar
  35. 35.
    Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC (2010) Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122:138–144CrossRefPubMedGoogle Scholar
  36. 36.
    Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefGoogle Scholar
  37. 37.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58:e212–e260CrossRefPubMedGoogle Scholar
  38. 38.
    Vriesendorp PA, Schinkel AF, Van Cleemput J, Willems R, Jordaens LJ, Theuns DA, van Slegtenhorst MA, de Ravel TJ, ten Cate FJ, Michels M (2013) Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J 166:496–502CrossRefPubMedGoogle Scholar
  39. 39.
    Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M, McKenna WJ, Elliott PM (2008) Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 10:507–513CrossRefPubMedGoogle Scholar
  40. 40.
    Brouwer WP, Baars EN, Germans T, de Boer K, Beek AM, van der Velden J, van Rossum AC, Hofman MB (2014) In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 16:28CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, Pastor A, Carr-White G, Razavi R, Schaeffter T, Nagel E (2013) Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 6:475–484CrossRefPubMedGoogle Scholar
  42. 42.
    Quarta G, Grasso A, Pasquale F, Flett AS, Sado DM, Bonini E, Ariti C, Prasad SK, Elliott PM, Moon JC (2011) Evolution and clinical importance of fibrosis in HCM. JACC Cardiovasc Imaging 4:1221–1223CrossRefPubMedGoogle Scholar
  43. 43.
    Todiere G, Aquaro GD, Piaggi P, Formisano F, Barison A, Masci PG, Strata E, Bacigalupo L, Marzilli M, Pingitore A, Lombardi M (2012) Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 60:922–929CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Akira Funada
    • 1
  • Hideaki Kanzaki
    • 1
  • Teruo Noguchi
    • 1
  • Yoshiaki Morita
    • 2
  • Yasuo Sugano
    • 1
  • Takahiro Ohara
    • 1
  • Takuya Hasegawa
    • 1
  • Hiromi Hashimura
    • 2
    • 3
  • Hatsue Ishibashi-Ueda
    • 3
  • Masafumi Kitakaze
    • 1
    • 4
  • Satoshi Yasuda
    • 1
  • Hisao Ogawa
    • 1
  • Toshihisa Anzai
    • 1
  1. 1.Department of Cardiovascular MedicineNational Cerebral and Cardiovascular CenterSuitaJapan
  2. 2.Department of RadiologyNational Cerebral and Cardiovascular CenterSuitaJapan
  3. 3.Department of PathologyNational Cerebral and Cardiovascular CenterSuitaJapan
  4. 4.Department of Clinical Research and DevelopmentNational Cerebral and Cardiovascular CenterSuitaJapan

Personalised recommendations